{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:37Z","timestamp":1790345017761,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020655","name":"European Health and Digital Executive Agency","doi-asserted-by":"publisher","award":["01057619"],"award-info":[{"award-number":["01057619"]}],"id":[{"id":"10.13039\/100020655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40273-026-01634-z","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:09:31Z","timestamp":1783361371000},"page":"1171-1187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SMART Planning of Early-Stage Health Economic Decision Models for Mechanism-Based\u00a0Precision\u00a0Treatments in Rare Cancers: An Application and Tool Update"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-1721","authenticated-orcid":false,"given":"Teebah","family":"Abu-Zahra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine E.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Changoer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas U.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mathes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana T.","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"10","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40273-025-01515-x","volume":"43","author":"T Abu-Zahra","year":"2025","unstructured":"Abu-Zahra T, et al. Can we make health economic decision models as simple as possible, but not simpler? Introducing SMART tool. Pharmacoeconomics. 2025;43(10):1235\u201350. https:\/\/doi.org\/10.1007\/s40273-025-01515-x.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1258\/135581904322987535","volume":"9","author":"P Barton","year":"2004","unstructured":"Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110\u20138. https:\/\/doi.org\/10.1258\/135581904322987535.","journal-title":"J Health Serv Res Policy"},{"issue":"8","key":"1634_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jval.2012.07.008","volume":"15","author":"P Tappenden","year":"2012","unstructured":"Tappenden P, et al. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health. 2012;15(8):1127\u201336. https:\/\/doi.org\/10.1016\/j.jval.2012.07.008.","journal-title":"Value Health"},{"issue":"1","key":"1634_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","volume":"9","author":"H Nada","year":"2024","unstructured":"Nada H, et al. New insights into protein\u2013protein interaction modulators in drug discovery and therapeutic advance. Signal Transduct Target Ther. 2024;9(1):341. https:\/\/doi.org\/10.1038\/s41392-024-02036-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales C, et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136\u201350. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1634_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7861\/clinmedicine.17-6-545","volume":"17","author":"HK Brittain","year":"2017","unstructured":"Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med (Lond). 2017;17(6):545\u201351. https:\/\/doi.org\/10.7861\/clinmedicine.17-6-545.","journal-title":"Clin Med (Lond)"},{"issue":"1","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt.2471","volume":"111","author":"HG Eichler","year":"2022","unstructured":"Eichler HG, et al. Precision reimbursement for precision medicine: using real-world evidence to evolve from trial-and-project to track-and-pay to learn-and-predict. Clin Pharmacol Ther. 2022;111(1):52\u201362. https:\/\/doi.org\/10.1002\/cpt.2471.","journal-title":"Clin Pharmacol Ther"},{"key":"1634_CR9","doi-asserted-by":"publisher","unstructured":"Tiriveedhi V. Impact of precision medicine on drug repositioning and pricing: a too small to thrive crisis. J Pers Med. 2018;8(4):36. https:\/\/doi.org\/10.3390\/jpm8040036.","DOI":"10.3390\/jpm8040036"},{"issue":"8","key":"1634_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.jval.2012.05.006","volume":"15","author":"E Faulkner","year":"2012","unstructured":"Faulkner E, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012;15(8):1162\u201371. https:\/\/doi.org\/10.1016\/j.jval.2012.05.006.","journal-title":"Value Health"},{"issue":"4","key":"1634_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70215","volume":"18","author":"MA Ahmed","year":"2025","unstructured":"Ahmed MA, et al. Unlocking the mysteries of rare disease drug development: a beginner\u2019s guide for clinical pharmacologists. Clin Transl Sci. 2025;18(4):e70215. https:\/\/doi.org\/10.1111\/cts.70215.","journal-title":"Clin Transl Sci"},{"issue":"6 Suppl","key":"1634_CR12","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jval.2013.06.008","volume":"16","author":"L Annemans","year":"2013","unstructured":"Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(6 Suppl):S20\u20136. https:\/\/doi.org\/10.1016\/j.jval.2013.06.008.","journal-title":"Value Health"},{"key":"1634_CR13","unstructured":"REPO4EU. REPO4EU. [accessed 2026 April 22]. https:\/\/repo4.eu\/."},{"issue":"1","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/ijmr.IJMR_915_14","volume":"145","author":"RK Pillai","year":"2017","unstructured":"Pillai RK, Jayasree K. Rare cancers: challenges & issues. Indian J Med Res. 2017;145(1):17\u201327. https:\/\/doi.org\/10.4103\/ijmr.IJMR_915_14.","journal-title":"Indian J Med Res"},{"issue":"Suppl 1","key":"1634_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000794","volume":"4","author":"S Cannizzo","year":"2018","unstructured":"Cannizzo S, et al. Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018;4(Suppl 1):e000794. https:\/\/doi.org\/10.1136\/rmdopen-2018-000794.","journal-title":"RMD Open"},{"issue":"1","key":"1634_CR16","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000507","volume":"37","author":"J Bouttell","year":"2021","unstructured":"Bouttell J, Briggs A, Hawkins N. A toolkit of methods of development-focused health technology assessment. Int J Technol Assess Health Care. 2021;37(1):e84. https:\/\/doi.org\/10.1017\/S0266462321000507.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1634_CR17","first-page":"30","volume":"8","author":"QT Nguyen","year":"2015","unstructured":"Nguyen QT, et al. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30\u201340.","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"1634_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13193-021-01429-y","volume":"13","author":"JB Shank","year":"2022","unstructured":"Shank JB, Are C, Wenos CD. Thyroid cancer: global burden and trends. Indian J Surg Oncol. 2022;13(1):40\u20135. https:\/\/doi.org\/10.1007\/s13193-021-01429-y.","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"1634_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1634_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061292","author":"B Schmidbauer","year":"2017","unstructured":"Schmidbauer B, et al. Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18061292.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1634_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.clon.2017.01.041","volume":"29","author":"DB Spielman","year":"2017","unstructured":"Spielman DB, et al. Rare thyroid malignancies: an overview for the oncologist. Clin Oncol (R Coll Radiol). 2017;29(5):298\u2013306. https:\/\/doi.org\/10.1016\/j.clon.2017.01.041.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic T, et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid. 2019;29(3):311\u201321. https:\/\/doi.org\/10.1089\/thy.2018.0509.","journal-title":"Thyroid"},{"issue":"7","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3390\/curroncol31070286","volume":"31","author":"F Volpe","year":"2024","unstructured":"Volpe F, et al. Current advances in radioactive iodine-refractory differentiated thyroid cancer. Curr Oncol. 2024;31(7):3870\u201384. https:\/\/doi.org\/10.3390\/curroncol31070286.","journal-title":"Curr Oncol"},{"issue":"23","key":"1634_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMc1613118","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(23):2307. https:\/\/doi.org\/10.1056\/NEJMc1613118.","journal-title":"N Engl J Med"},{"issue":"3","key":"1634_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184\u201399. https:\/\/doi.org\/10.1038\/nrc3431.","journal-title":"Nat Rev Cancer"},{"key":"1634_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.860615","volume":"13","author":"B Shi","year":"2022","unstructured":"Shi B, et al. Cost-effectiveness of apatinib and cabozantinib for the treatment of radioiodine-refractory differentiated thyroid cancer. Front Pharmacol. 2022;13:860615. https:\/\/doi.org\/10.3389\/fphar.2022.860615.","journal-title":"Front Pharmacol"},{"key":"1634_CR27","doi-asserted-by":"publisher","unstructured":"Hiromasa T, et al. Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights. Eur Thyroid J. 2025;14(2):e240319. https:\/\/doi.org\/10.1530\/ETJ-24-0319.","DOI":"10.1530\/ETJ-24-0319"},{"issue":"2","key":"1634_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40258-022-00774-5","volume":"21","author":"EA Boudewijns","year":"2023","unstructured":"Boudewijns EA, et al. Headroom analysis for early economic evaluation: a systematic review. Appl Health Econ Health Policy. 2023;21(2):195\u2013204. https:\/\/doi.org\/10.1007\/s40258-022-00774-5.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"1634_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1057\/palgrave.jcb.3050062","volume":"13","author":"E Cosh","year":"2007","unstructured":"Cosh E, et al. Investing in new medical technologies: a decision framework. J Commer Biotechnol. 2007;13(4):263\u201371. https:\/\/doi.org\/10.1057\/palgrave.jcb.3050062.","journal-title":"J Commer Biotechnol"},{"key":"1634_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165261","author":"G Miguel Llordes","year":"2023","unstructured":"Miguel Llordes G, et al. Epidemiology, diagnostic strategies, and therapeutic advances in diffuse midline glioma. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12165261.","journal-title":"J Clin Med"},{"issue":"1","key":"1634_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad040","volume":"5","author":"N Jovanovich","year":"2023","unstructured":"Jovanovich N, et al. Pediatric diffuse midline glioma: understanding the mechanisms and assessing the next generation of personalized therapeutics. Neuro-Oncol Adv. 2023;5(1):vdad040. https:\/\/doi.org\/10.1093\/noajnl\/vdad040.","journal-title":"Neuro-Oncol Adv"},{"issue":"Supplement_4","key":"1634_CR32","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","volume":"27","author":"M Price","year":"2025","unstructured":"Price M, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022. Neuro Oncol. 2025;27(Supplement_4):iv1\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noaf194.","journal-title":"Neuro Oncol"},{"key":"1634_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101814","author":"M Mandorino","year":"2024","unstructured":"Mandorino M, et al. Pediatric diffuse midline glioma H3K27-altered: from developmental origins to therapeutic challenges. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16101814.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1634_CR34","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"1634_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jconrel.2023.11.037","volume":"365","author":"PJ Martinez","year":"2024","unstructured":"Martinez PJ, Green AL, Borden MA. Targeting diffuse midline gliomas: the promise of focused ultrasound-mediated blood-brain barrier opening. J Control Release. 2024;365:412\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.037.","journal-title":"J Control Release"},{"issue":"8","key":"1634_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza NA, Monje M. Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials. Curr Treat Opt Neurol. 2019;21(8):37. https:\/\/doi.org\/10.1007\/s11940-019-0577-y.","journal-title":"Curr Treat Opt Neurol"},{"key":"1634_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246251","author":"E Hayden","year":"2021","unstructured":"Hayden E, et al. Therapeutic targets in diffuse midline gliomas\u2014an emerging landscape. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13246251.","journal-title":"Cancers (Basel)"},{"key":"1634_CR38","unstructured":"Nederland Z. Guideline for economic evaluations in healthcare: 2024 version. Series. 2024. https:\/\/english.zorginstituutnederland.nl\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare."},{"key":"1634_CR39","unstructured":"(HAS), H.A.d.S. Choices in methods for economic evaluation: Valuing health technologies\u2014methodological guidance. Series. 2020. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2020-11\/methodological_guidance_2020_-choices_in_methods_for_economic_evaluation.pdf."},{"key":"1634_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103453","volume":"69","author":"G Price","year":"2021","unstructured":"Price G, et al. Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine. 2021;69:103453. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103453.","journal-title":"EBioMedicine"},{"key":"1634_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050333","author":"A Ieni","year":"2021","unstructured":"Ieni A, et al. Intratumoral heterogeneity in differentiated thyroid tumors: an intriguing reappraisal in the era of personalized medicine. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11050333.","journal-title":"J Pers Med"},{"key":"1634_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.06.002","volume":"99","author":"LE Clegg","year":"2015","unstructured":"Clegg LE, Mac Gabhann F. Molecular mechanism matters: benefits of mechanistic computational models for drug development. Pharmacol Res. 2015;99:149\u201354. https:\/\/doi.org\/10.1016\/j.phrs.2015.06.002.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1634_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793\u20135. https:\/\/doi.org\/10.1056\/NEJMp1500523.","journal-title":"N Engl J Med"},{"issue":"8","key":"1634_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.67891","volume":"16","author":"D S","year":"2024","unstructured":"S D, K R. A review of the regulatory challenges of personalized medicine. Cureus. 2024;16(8):e67891. https:\/\/doi.org\/10.7759\/cureus.67891.","journal-title":"Cureus"},{"issue":"6","key":"1634_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104008","volume":"29","author":"T Abu-Zahra","year":"2024","unstructured":"Abu-Zahra T, et al. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework. Drug Discov Today. 2024;29(6):104008. https:\/\/doi.org\/10.1016\/j.drudis.2024.104008.","journal-title":"Drug Discov Today"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01634-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01634-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:42:33Z","timestamp":1790343753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01634-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01634-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TA: Writing, conceptualization, reviewing and editing of the original draft, writing and editing of the research protocol, methodology development, investigation, visualization, validation, data curation, and formal analysis. SG: Conceptualization, review and editing of the original draft, validation, visualization, supervision, and project administration. PC: Conceptualization and review and editing of original draft. NG: Conceptualization and review and editing of original draft. SM: Conceptualization and review and editing of original draft. RNM: Conceptualization and review and editing of original draft. MJ: Conceptualization, review and editing of the original draft, validation, visualization, supervision, project administration, and funding acquisition.\u00a0We hereby confirm that all authors have read and approved the final version of the article prior to submission.","order":6,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}